EQL PHARMA AB (7JK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, EQL PHARMA AB (7JK) has a cash flow conversion efficiency ratio of 0.050x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€13.44 Million ≈ $15.72 Million USD) by net assets (€269.78 Million ≈ $315.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of EQL PHARMA AB to measure how much of total assets are equity-financed.
EQL PHARMA AB - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how EQL PHARMA AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check EQL PHARMA AB (7JK) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
EQL PHARMA AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EQL PHARMA AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KB No4 SPAC
KQ:205500
|
-0.171x |
|
Cedergrenska AB
ST:CEDER
|
0.616x |
|
A SPAC II Acquisition Corp. Ordinary Shares
NASDAQ:ASCB
|
0.036x |
|
3REN Berhad
KLSE:0328
|
-0.029x |
|
Aikchol Hospital Public Company Limited
BK:AHC
|
0.033x |
|
Sinkang Industries Co Ltd
TW:2032
|
0.011x |
|
Sangsangin Co. Ltd
KQ:038540
|
1.338x |
|
Aker Technology Co Ltd
TWO:6174
|
0.024x |
Annual Cash Flow Conversion Efficiency for EQL PHARMA AB (2022–2025)
The table below shows the annual cash flow conversion efficiency of EQL PHARMA AB from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market value of EQL PHARMA AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €221.03 Million ≈ $258.41 Million |
€-24.65 Million ≈ $-28.82 Million |
-0.112x | -73.31% |
| 2024-03-31 | €177.73 Million ≈ $207.78 Million |
€-11.44 Million ≈ $-13.37 Million |
-0.064x | -136.06% |
| 2023-03-31 | €154.75 Million ≈ $180.92 Million |
€27.62 Million ≈ $32.29 Million |
0.178x | -47.26% |
| 2022-03-31 | €123.63 Million ≈ $144.53 Million |
€41.83 Million ≈ $48.90 Million |
0.338x | -- |
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.